[go: up one dir, main page]

MA30198B1 - Inhibiteurs de la protease ns3 du vhc - Google Patents

Inhibiteurs de la protease ns3 du vhc

Info

Publication number
MA30198B1
MA30198B1 MA30655A MA30655A MA30198B1 MA 30198 B1 MA30198 B1 MA 30198B1 MA 30655 A MA30655 A MA 30655A MA 30655 A MA30655 A MA 30655A MA 30198 B1 MA30198 B1 MA 30198B1
Authority
MA
Morocco
Prior art keywords
hcv
protease
inhibitors
hepatitis
virus
Prior art date
Application number
MA30655A
Other languages
English (en)
Inventor
M Katharine Holloway
Nigel J Liverton
Steven W Ludmerer
John A Mccauley
David B Olsen
Michael T Rudd
Joseph P Vacca
Charles J Mcintyre
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30198B1 publication Critical patent/MA30198B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés macrocycliques de formule (I) qui sont utiles comme inhibiteurs de la protéase NS3 du virus de l'hépatite C (VHC), leur synthèse, et leur usage pour le traitement ou la prévention des infections par le VHC.
MA30655A 2005-07-20 2008-02-18 Inhibiteurs de la protease ns3 du vhc MA30198B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70076405P 2005-07-20 2005-07-20
US72456605P 2005-10-07 2005-10-07

Publications (1)

Publication Number Publication Date
MA30198B1 true MA30198B1 (fr) 2009-02-02

Family

ID=37467463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30655A MA30198B1 (fr) 2005-07-20 2008-02-18 Inhibiteurs de la protease ns3 du vhc

Country Status (37)

Country Link
US (2) US7470664B2 (fr)
EP (2) EP1924593B9 (fr)
JP (2) JP4621282B2 (fr)
KR (1) KR101296095B1 (fr)
AR (1) AR057456A1 (fr)
AT (1) ATE443075T1 (fr)
AU (1) AU2006276189B9 (fr)
BR (1) BRPI0613633A2 (fr)
CA (1) CA2615022C (fr)
CR (1) CR9621A (fr)
CY (1) CY1109671T1 (fr)
DE (1) DE602006009280D1 (fr)
DK (1) DK1924593T3 (fr)
DO (2) DOP2006000171A (fr)
EA (1) EA013331B1 (fr)
EC (1) ECSP088107A (fr)
ES (2) ES2446015T3 (fr)
GE (1) GEP20115248B (fr)
GT (1) GT200600317A (fr)
HN (1) HN2008000087A (fr)
HR (1) HRP20090627T1 (fr)
IL (1) IL188618A0 (fr)
JO (1) JO2593B1 (fr)
MA (1) MA30198B1 (fr)
MX (1) MX2008000866A (fr)
MY (1) MY142240A (fr)
NO (1) NO20080879L (fr)
NZ (1) NZ565223A (fr)
PE (1) PE20070364A1 (fr)
PL (1) PL1924593T3 (fr)
PT (1) PT1924593E (fr)
RS (1) RS51101B (fr)
SG (1) SG164376A1 (fr)
SI (1) SI1924593T1 (fr)
TN (1) TNSN08033A1 (fr)
TW (1) TWI387603B (fr)
WO (2) WO2007015855A1 (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2006242475B2 (en) * 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
RU2435778C2 (ru) * 2005-07-04 2011-12-10 Заннан Сайтех Ко., Лтд. Лиганд комплекса рутения, комплекс рутения, катализатор комплекса рутения и способы его получения и применения
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
CN101263156A (zh) 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
RU2008107972A (ru) * 2005-08-01 2009-09-10 Мерк энд Ко., Инк. (US) Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
CN101415705B (zh) * 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US8138164B2 (en) * 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309546A1 (en) * 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
US8309540B2 (en) * 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
EP2083844B1 (fr) * 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
EP2086982B1 (fr) * 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103224506A (zh) * 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2481807A3 (fr) 2007-03-09 2013-04-03 Merck Sharp & Dohme Corp. Résistance HCV in vivo à des inhibiteurs anti-viraux
DE602008003922D1 (de) * 2007-04-24 2011-01-20 Hoffmann La Roche Verfahren für hcv-proteasehemmerzwischenprodukt
EP2160392A2 (fr) * 2007-05-03 2010-03-10 Intermune, Inc. Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c
WO2008141227A1 (fr) 2007-05-10 2008-11-20 Intermune, Inc. Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c
AU2008277442A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
WO2009010804A1 (fr) * 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composes macrocycliques servant d'agents antiviraux
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8304385B2 (en) 2007-11-14 2012-11-06 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
CN101980602A (zh) 2007-12-14 2011-02-23 益安药业 大环肟基丙型肝炎丝氨酸蛋白酶抑制剂
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
WO2009085978A1 (fr) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Inhibiteurs de protéase de sérine de virus de l'hépatite c d'oxime carbocyclique couronnés
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CN104557861A (zh) 2007-12-21 2015-04-29 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2237666A4 (fr) 2007-12-21 2012-05-16 Avila Therapeutics Inc Inhibiteurs de hcv protéase et leurs utilisations
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2015224437B2 (en) * 2007-12-21 2017-05-25 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CN101977915B (zh) * 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
EP2268285B1 (fr) 2008-02-25 2018-06-27 Merck Sharp & Dohme Corp. Composés thérapeutiques
CN102015652A (zh) * 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2720850A1 (fr) * 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de la protease hcv ns3
WO2009148923A1 (fr) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Inhibiteurs du virus de l’hépatite c
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2310095T3 (pl) * 2008-07-22 2013-03-29 Msd Italia Srl Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201034663A (en) * 2008-12-19 2010-10-01 Gilead Sciences Inc HCV NS3 protease inhibitors
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
WO2010082050A1 (fr) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
CN102458444A (zh) * 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
EP2432318A4 (fr) * 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc Inhibiteurs de la protéase ns3 du virus de l'hépatite c bimacrocyclique
WO2011014487A1 (fr) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du virus de l'hépatite c
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
AU2010286681A1 (en) * 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
WO2011038293A1 (fr) * 2009-09-28 2011-03-31 Intermune, Inc. Inhibiteurs peptiques cycliques de la réplication du virus de l'hépatite c
WO2011049908A2 (fr) 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Composés bismacrocycliques à titre d'inhibiteurs du virus de l'hépatite c
CN102140100B (zh) 2010-01-27 2014-06-11 爱博新药研发(上海)有限公司 高效抑制丙型肝炎病毒的多环化合物及其制备方法和用途
IN2012MN02896A (fr) 2010-06-24 2015-06-12 Panmed Ltd
KR101894704B1 (ko) 2010-09-21 2018-09-05 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
EP2635570B1 (fr) 2010-11-01 2017-12-13 RFS Pharma, LLC. Nouveaux inhibiteurs spécifiques de la protéase ns3 du vhc
BR112013010372A2 (pt) 2010-12-14 2016-07-05 Merck Sharp & Dohme composto, e, método para preparar um composto
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (fr) * 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 Composé hétérocyclique macrocyclique pour l'inhibition du virus de l'hépatite c, sa préparation et ses applications
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
EP2744507A4 (fr) 2011-08-19 2015-01-28 Merck Sharp & Dohme Formes cristallines d'un inhibiteur de protéase du vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (fr) 2011-10-21 2013-06-12 Abbvie Inc. Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2012332832A1 (en) * 2011-10-31 2014-04-17 Msd Italia S.R.L. Compositions useful for the treatment of viral diseases
WO2013106631A1 (fr) * 2012-01-11 2013-07-18 Abbvie Inc. Procédés de préparation d'inhibiteurs de protéase du vhc
CA2858814A1 (fr) 2012-01-12 2013-07-18 Rfs Pharma, Llc Inhibiteurs de la protease ns3 du vhc
CN102617705B (zh) 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
TW201408669A (zh) 2012-08-08 2014-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
JP6438417B2 (ja) * 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
WO2015057611A1 (fr) 2013-10-18 2015-04-23 Merck Sharp & Dohme Corp. Procédés et intermédiaires pour préparer des macrolactames
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3454862B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
FR2722210B1 (fr) * 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
EP1106626B1 (fr) 1998-08-10 2003-05-28 Hokkaido Electric Power Company, Incorporated Preparation de glycopeptides ordinaires
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
CA2348234A1 (fr) 1998-10-29 2000-05-11 Chunjian Liu Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6395763B1 (en) 1999-06-25 2002-05-28 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of IMPDH
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
MXPA02008078A (es) 2000-02-18 2002-11-29 Julio Javier Cristiani Metodo para el tratamiento o prevencion de infecciones por flavivirus utilizando analogos de nucleosidos.
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
AU2001253206A1 (en) 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
ATE414520T1 (de) 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AU2001284773B2 (en) 2000-08-10 2004-08-05 Trustees Of Boston College Recyclable metathesis catalysts
US6955174B2 (en) * 2000-08-18 2005-10-18 Uryovascular Systems, Inc. Cryotherapy method for detecting and treating vulnerable plaque
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2001282528A1 (en) 2000-09-01 2002-03-22 Shionogi And Co., Ltd. Compounds having anti-hepatitis c virus effect
CA2426187C (fr) 2000-10-18 2011-08-16 Pharmasset Limited Nucleosides modifies pour le traitement des infections virales et de la proliferation cellulaire anormale
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
CA2437209A1 (fr) 2000-12-26 2002-07-04 Mitsubishi Pharma Corporation Remedes pour l'hepatite c
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7544374B2 (en) 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
WO2003026675A1 (fr) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Procedes et compositions pour traiter des flavivirus et des pestivirus au moyen d'un nucleoside modifie en position 4'
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
EP1465862A1 (fr) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CA2369711A1 (fr) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2003068244A1 (fr) 2002-02-13 2003-08-21 Merck & Co., Inc. Procede d'inhibition de la replication d'orthopoxvirus avec des composes de nucleoside
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2488484A1 (fr) 2002-06-27 2004-01-08 Merck & Co., Inc. Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004007512A2 (fr) 2002-07-16 2004-01-22 Merck & Co., Inc. Derives de nucleosides utilises en tant qu'inhibiteurs de l'arn polymerase virale arn-dependante
AU2003254657A1 (en) 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
MXPA05001298A (es) 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CA2515216A1 (fr) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la serine protease de l'hepatite c
US20040254159A1 (en) 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
EP1601685A1 (fr) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Composes d'inhibition de l'hepatite c
CN100363055C (zh) 2003-04-02 2008-01-23 贝林格尔·英格海姆国际有限公司 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
AR044129A1 (es) 2003-05-06 2005-08-24 Altana Pharma Ag Compuestos intermedios de imidazopiridina. proceso de preparacion.
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US6955184B2 (en) 2003-05-29 2005-10-18 Honeywell International, Inc. Pneumatic generator system for simulating operating conditions of an aircraft
KR20060026426A (ko) 2003-06-19 2006-03-23 에프. 호프만-라 로슈 아게 4'-아지도 뉴클레오사이드 유도체의 제조 방법
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
GEP20104926B (en) 2004-03-30 2010-03-25 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
GB0519797D0 (en) 2005-09-29 2005-11-09 Istituto Di Ricerche D Biolog Therapeutic agents
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008019303A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
EP2083844B1 (fr) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8304385B2 (en) 2007-11-14 2012-11-06 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
JP5345117B2 (ja) 2013-11-20
WO2007015787A1 (fr) 2007-02-08
GEP20115248B (en) 2011-07-11
EA200800371A1 (ru) 2008-06-30
PT1924593E (pt) 2009-12-07
EP1910404A1 (fr) 2008-04-16
ATE443075T1 (de) 2009-10-15
GT200600317A (es) 2007-01-29
CA2615022C (fr) 2012-09-04
TNSN08033A1 (en) 2009-07-14
CY1109671T1 (el) 2014-02-12
AR057456A1 (es) 2007-12-05
KR101296095B1 (ko) 2013-08-20
PL1924593T3 (pl) 2010-02-26
TW200740850A (en) 2007-11-01
DOP2009000094A (es) 2009-06-30
US8216999B2 (en) 2012-07-10
ES2446015T3 (es) 2014-03-06
US7470664B2 (en) 2008-12-30
ES2332821T3 (es) 2010-02-12
CA2615022A1 (fr) 2007-02-08
SI1924593T1 (sl) 2010-04-30
AU2006276189B9 (en) 2012-02-02
JP2009502793A (ja) 2009-01-29
HK1121169A1 (en) 2009-04-17
TWI387603B (zh) 2013-03-01
DK1924593T3 (da) 2010-01-25
EP1924593B1 (fr) 2009-09-16
DOP2006000171A (es) 2007-02-15
RS51101B (sr) 2010-10-31
EP1910404B1 (fr) 2013-11-27
SG164376A1 (en) 2010-09-29
ECSP088107A (es) 2008-02-20
JP2011079828A (ja) 2011-04-21
EP1924593B8 (fr) 2009-11-18
WO2007015855A1 (fr) 2007-02-08
US20090124661A1 (en) 2009-05-14
JO2593B1 (en) 2011-02-27
HRP20090627T1 (hr) 2010-01-31
PE20070364A1 (es) 2007-05-12
MX2008000866A (es) 2008-03-18
KR20080027860A (ko) 2008-03-28
HN2008000087A (es) 2010-12-27
BRPI0613633A2 (pt) 2011-01-18
DE602006009280D1 (de) 2009-10-29
CR9621A (es) 2008-02-21
NO20080879L (no) 2008-04-17
MY142240A (en) 2010-11-15
JP4621282B2 (ja) 2011-01-26
IL188618A0 (en) 2008-04-13
ES2446015T9 (es) 2014-07-16
EP1924593A1 (fr) 2008-05-28
NZ565223A (en) 2010-09-30
US20070027071A1 (en) 2007-02-01
EP1924593B9 (fr) 2010-02-17
AU2006276189A1 (en) 2007-02-08
EP1910404B9 (fr) 2014-05-21
EA013331B1 (ru) 2010-04-30
AU2006276189B2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
WO2006119061A3 (fr) Inhibiteurs de la protease ns3 du vhc
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA33360B1 (fr) Composés antiviraux hétérocycliques
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
ATE512976T1 (de) Hemmer des hepatitis-c-virus
MXPA04000293A (es) Inhibidores de serina proteasa biciclica de puente.
UY28323A1 (es) Compuestos inhibidores de la hepatitis c
EP1615914A4 (fr) Antagonistes des recepteurs de cgrp
NO20091704L (no) Inhibitorer av hepatitt C virus
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
NO20091707L (no) Inhibitorer av hepatitt C virus
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
NO20091706L (no) Inhibitorer av hepatitt C virus
ECSP066456A (es) Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
EP2374464A3 (fr) Inhibition de la protéase N3S-NS4A du virus de l'hépatite C
WO2004106293A3 (fr) Composes tricycliques a base d'oxazolo[4,5-b]pyridine condensee a un imidazo et de thiazolo[4,5-b]pyridine condensee a un imidazo, et compositions pharmaceutiques renfermant ceux-ci
TNSN07240A1 (en) Compounds for flaviviridae treatment
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren